生存素:生长抑素受体配体耐药性的潜在标志物
本研究在52例生长激素瘤组织芯片中分析生存素、4EBP1、SSTR2、Ki-67和细胞角蛋白18的表达,并在34例接受生长抑素受体配体(SRL)治疗的患者中评估耐药性。结果显示低生存素表达与第一代SRL耐药相关(P=0.04),但与肿瘤侵袭性无关,提示生存素可能是生长激素瘤SRL耐药的预测标志物。
要点
- 低生存素表达与第一代SRL耐药相关(P=0.04),但与肿瘤侵袭性无关。
- T2WI高信号、年轻年龄、稀疏颗粒腺瘤、术后高GH和IGF-1水平及术后大肿瘤体积亦与耐药相关。
- 低SSTR2表达与肿瘤侵袭性相关(P=0.03),而生存素、4EBP1、Ki-67和颗粒模式与侵袭无关。
核心结论
- 本研究表明低生存素表达可预测生长激素瘤对第一代SRL的耐药性,但不能预测肿瘤侵袭性。
研究设计与样本
- 研究分析了52例生长激素瘤样本的组织芯片中生存素、4EBP1、SSTR2、Ki-67和细胞角蛋白18的免疫染色,并在34例接受SRL治疗的患者中评估耐药性。
主要发现
- 低生存素表达(P=0.04)、T2WI高信号(P=0.01)、年轻年龄(P=0.01)、稀疏颗粒腺瘤(P=0.04)、术后高GH水平(P=0.049)和IGF-1水平(P<0.001)以及术后大肿瘤体积(P=0.02)与第一代SRL耐药相关。
- 低生存素表达(P=0.04)、低SSTR2表达(P=0.01)和高4EBP1表达(P=0.001)与稀疏颗粒腺瘤相关。
- 年轻年龄(P=0.03)、术前大肿瘤(P=0.04)和术后大肿瘤(P=0.006)、低SSTR2表达(P=0.03)以及高基线GH(P=0.01)和IGF-1(P=0.02)水平与肿瘤侵袭性相关。
- 生存素、4EBP1、Ki-67和颗粒模式与肿瘤侵袭无关。
关键数值与推荐
- 低生存素表达与第一代SRL耐药相关(P=0.04)。
- 低SSTR2表达与肿瘤侵袭性相关(P=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Invasive and somatostatin receptor ligand (SRL)-resistant pituitary tumors represent a challenge in the clinical practice of endocrinologists. Efforts have been made to elucidate reliable makers for both. Survivin and eukaryotic translation initiation factor-binding protein 1 (4EBP1) are upregulated in several cancers and involved in apoptosis and cell proliferation. OBJECTIVE: We explored the role of these markers in somatotropinomas. METHODS: Immunostains for survivin and 4EBP1, and also for somatostatin receptor type 2 (SSTR2), Ki-67, and cytokeratin 18, were analyzed in tissue microarrays containing 52 somatotropinoma samples. Tumor invasiveness was evaluated in all samples while drug resistance was evaluated in 34 patients who received SRL treatment. All these parameters were correlated with first-generation SRL (fg-SRL) responsiveness and tumor invasiveness. RESULTS: Low survivin expression (P = 0.04), hyperintense signal on T2 weighted image (T2WI) (P = 0.01), younger age (P = 0.01), sparsely granular adenomas (SGA) (P = 0.04), high postoperative growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels (P = 0.049 and P < 0.001, respectively), and large postoperative tumor size (P = 0.02) were associated with resistance to fg-SRL. Low survivin and SSTR2 expression and high 4EBP1 expression were associated with SGA (P = 0.04, P = 0.01, and P = 0.001, respectively). Younger age (P = 0.03), large tumor pre- and postoperative (P = 0.04 and P = 0.006, respectively), low SSTR2 expression (P = 0.03), and high baseline GH and IGF-1 (P = 0.01 and P = 0.02, respectively) were associated with tumor invasiveness. However, survivin, 4EBP1, Ki-67, and granulation patterns were not associated with tumor invasion. CONCLUSION: This study suggests that low survivin expression is predictive of resistance to fg-SRL in somatotropinomas, but not of tumor invasiveness.
引用
- Herkenhoff CGB, Trarbach EB, Batista RL, et al. Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands. J Clin Endocrinol Metab. 2023. PMID: 36273993. doi:10.1210/clinem/dgac610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。